The use of high-dose therapy of ER blocker tamoxifen was found to increase one-year and median survival when used to treat stage III-IV NSCLC in combination with chemotherapy compared to patients who only received chemotherapy [153]. Here, ESR1 is linked to non-small cell lung carcinoma.